Please login to the form below

Not currently logged in
Email:
Password:

Medigene

This page shows the latest Medigene news and features for those working in and with pharma, biotech and healthcare.

Medigene buys cancer vaccine start-up

Medigene buys cancer vaccine start-up

Medigene buys cancer vaccine start-up. Acquires Trianta to boost immuno-oncology business. ... The new Medigene will combine proprietary immunotherapy platforms with late stage drug candidates and a marketed product," said Medigene chief executive Frank

Latest news

  • CMPT announces CEO and loan investment

    He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji

  • Astellas acquires European rights for Eligard

    Previously, Astellas was MediGene's European marketing partner for Eligard, having acquired these rights from TOLMAR Therapeutics in 2001. ... MediGene will also receive single-digit royalties on future net European product sales.

  • A competitive edge

    Haemophilus infections, hepatitis B. India. Polyphenon E . Veregen (Medigene AG). Genital warts .

  • Pharma news in brief

    At the outset of marketing, MediGene will receive a milestone payment from its marketing partner Astellas Pharma Europe. ... MediGene also receives royalties on the sales of Eligard. Teva launches generic Wellbutrin Xl tablets.

  • Hexal co-founders continue biotech buy up

    Hexal co-founders continue biotech buy up. The co-founders of Hexal are mulling further purchases in the biotech industry after buying a stake in MediGene. ... MediGene increasing registered share capital from EUR 30.8m to EUR 33.9m.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Firstly reviewing the licences and collaborations:. bluebird bio gained access to Medigene's T cell receptor platform for the development of TCR cancer immunotherapy candidates for four indications (not disclosed) Bluebird ... 1, 695. Medigene /Bluebird

  • Pharma deals during January 2014 Pharma deals during January 2014

    An interesting biotech:biotech deal was the acquisition of Trianta by Medigene, although the value at $8m does not feature in our top table.

  • Interview: Yoshihiko Hatanaka, CEO and president, Astellas Interview: Yoshihiko Hatanaka, CEO and president, Astellas

    It acquired the European marketing rights to Eligard, a prostate cancer drug, from MediGene via this route and is co-developing a compound for acute myeloid leukaemia with Ambit.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Dave Lemus joins Proteros as an executive board member Dave Lemus joins Proteros as an executive board member

    Dave Lemus joins Proteros as an executive board member. He joins the German biotech’s board from Medigene. ... Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an

  • Apeiron bolsters management board Apeiron bolsters management board

    During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

  • Lanthio Pharma bolsters management team Lanthio Pharma bolsters management team

    Prior to this, he held the role of chief medical and development officer at both Medigene and TopoTarget, and served as a medical director at MorphoSys.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics